QL1A Stock Overview
Provides diagnostic testing solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
QuidelOrtho Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.40 |
| 52 Week High | US$45.40 |
| 52 Week Low | US$21.20 |
| Beta | 0.13 |
| 1 Month Change | 15.79% |
| 3 Month Change | -32.31% |
| 1 Year Change | -31.96% |
| 3 Year Change | -71.87% |
| 5 Year Change | -82.97% |
| Change since IPO | 594.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| QL1A | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -11.4% | -1.2% | 0.5% |
| 1Y | -32.0% | -11.8% | 15.8% |
Return vs Industry: QL1A underperformed the German Medical Equipment industry which returned -11.8% over the past year.
Return vs Market: QL1A underperformed the German Market which returned 15.8% over the past year.
Price Volatility
| QL1A volatility | |
|---|---|
| QL1A Average Weekly Movement | 13.6% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: QL1A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: QL1A's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 6,600 | Brian Blaser | www.quidelortho.com |
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
QuidelOrtho Corporation Fundamentals Summary
| QL1A fundamental statistics | |
|---|---|
| Market cap | €1.80b |
| Earnings (TTM) | -€316.91m |
| Revenue (TTM) | €2.44b |
Is QL1A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QL1A income statement (TTM) | |
|---|---|
| Revenue | US$2.76b |
| Cost of Revenue | US$1.47b |
| Gross Profit | US$1.30b |
| Other Expenses | US$1.66b |
| Earnings | -US$358.70m |
Last Reported Earnings
Mar 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.30 |
| Gross Margin | 46.94% |
| Net Profit Margin | -12.97% |
| Debt/Equity Ratio | 83.3% |
How did QL1A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 21:49 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2025/03/30 |
| Annual Earnings | 2024/12/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
QuidelOrtho Corporation is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Owczarski | Avondale Partners |
| Mark Massaro | Canaccord Genuity |
| Patrick Donnelly | Citigroup Inc |